Tyrosine Kinase Signaling in Cancer, Disease, & Development

描述（由申请人提供）：酪氨酸激酶与恶性疾病发展的最初鉴定和联系开辟了肿瘤学的一个全新领域。随着临床中几种酪氨酸激酶的成功治疗靶点继续扩大这一学科和制药行业，酪氨酸激酶在癌症中的重要性和日益增长的兴趣的证据继续有增无减。人类基因组的完整测序确定了额外的酪氨酸激酶，其中许多仍在表征中。高通量测序和快速基因组图谱的出现进一步提高了酪氨酸激酶及其效应物在发育、免疫和退行性疾病中的重要性，并催生了这些学科的治疗发展。该领域定义了当前和未来癌症靶向治疗和个性化医疗的最新技术，并正在迅速扩展到其他领域。今天该领域面临的挑战是提高我们的知识以开发更好的治疗策略，更好地了解当治疗无效时哪里出了问题，并弥合科学家和诊所之间的差距。支持和保留新的年轻研究人员在该领域是至关重要的填补空白和克服这些挑战。FASEB 2012酪氨酸激酶信号在癌症、发展和疾病会议中的具体目标有三个。第一个目标是传播和合成有关酪氨酸激酶的最新知识和最新技术，因为它涉及结构，调节，信号机制，对正常和癌症生物学的影响以及药物靶向。目的是了解它们的突变或异常表达是如何导致疾病的。这将通过主题演讲和全体演讲、基于精选摘要的简短演讲、问答环节、海报环节和非正式讨论来实现。第二个目标是加强相互作用，促进合作和转化研究，以帮助将新疗法带到临床。其目标是在科学家和带来更好治疗方法所需的技术之间建立桥梁。这将通过举办一个由行业赞助的强调翻译的研讨会来实现。第三个目标是通过支持有前途的年轻学员，对未来进行智力和经济上的投资。目标是

DESCRIPTION (provided by applicant): The original identification and linkage of tyrosine kinases to the development of malignant disease opened an entire new field in oncology. Continued proof of the importance and growing interest in tyrosine kinases in cancer continues unabated, as the successful therapeutic targeting of several tyrosine kinases in the clinic continues to expand both the discipline and the pharmaceutical industry. The complete sequencing of the human genome identified additional tyrosine kinases, many of which are still being characterized. The advent of high throughput sequencing and rapid genomic mapping have further advanced the importance of tyrosine kinases and their effectors in developmental, immunological, and degenerative diseases and spawned therapeutic development in these disciplines. This field defines the current and future state-of-the-art of targeted therapies and personalized medicine in cancer and is rapidly expanding to other areas. The challenges facing the field today are to improve our knowledge to develop better therapeutic strategies, to better understand what goes wrong when a therapy doesn't work, and bridge the gap between the scientists and the clinic. Support and retention of new young investigators in the field is of paramount importance for filling the gaps and over- coming these challenges. There are three specific objectives of the FASEB 2012 Tyrosine Kinase Signaling in Cancer, Development, and Disease Conference. The first objective is to disseminate and synthesize the most up-to-date knowledge and newest technologies surrounding tyrosine kinases, as it relates to structure, regulation, signaling mechanisms, impact on normal and cancer biology, and drug targeting. The goal is to under- stand how their mutation or aberrant expression leads to disease. This will be accomplished through keynote and plenary speakers, short presentations based on selected abstracts, question and answer sessions, poster sessions, and informal discussion. The second objective is to enhance interactions that promote collaboration and translational research to help bring new therapies to the clinic. The goal is to build the bridges between scientists and the technologies that are needed to lead to better therapeutics. This will be accomplished by, hosting an industry-sponsored workshop emphasizing translation. The third objective is to invest intellectually and financially in the future by supporting promising young trainees. The goal is to encourage trainees to be successful and stay in the field by providing intellectual support through discussions with senior scientists, poster sessions, opportunities to speak, awards that recognize their achievements, and by providing financial support with competitive travel awards. The expected outcomes are increased collaborations, retention of young scientists in the field, identification of new developmental processes and diseases linked to tyrosine kinase signaling, and exploration of new avenues and approaches for identifying and developing therapeutic tar- gets and strategies to combat cancer, developmental deficiencies, and other diseases. 1) continue the in-depth structural, functional, and mechanistic characterization of tyrosine kinases, their regulators, and downstream effectors, 2) understand how their mutation or aberrant expression leads to disease, 3) present the successes and controversies associated with therapeutic targeting of these molecules, 4) build the bridges between scientists and the technologies that are needed to lead to better therapeutics, and 5) support and encourage trainees to be successful and stay in the field. PUBLIC HEALTH RELEVANCE: This application requests funding to provide partial support of a conference focused on the roles of tyrosine kinases in normal biology and cancer. Tyrosine kinases are frequently abnormal in cancer cells and are the fundamental basis for the recent development of targeted-therapies and personalized medicine in cancer treatment. Participants at this conference will be exposed to the challenges and barriers of tyrosine kinase-based therapeutics, be provided with ideas on how to address them, and be encouraged to incorporate these ideas into their future research programs. Only through this kind of intense immersion and focus, that is characteristic of small conferences such as this one, can we hope to be successful at breaking down the barriers that prevent a 100% success rate for curing cancer and alleviating patient suffering.